Unique ID issued by UMIN | UMIN000040333 |
---|---|
Receipt number | R000046025 |
Scientific Title | Fact-finding survey on subclinical infection of SARS-CoV-2 in Kanagawa Prefecture |
Date of disclosure of the study information | 2020/05/08 |
Last modified on | 2022/11/08 10:48:46 |
Fact-finding survey on subclinical infection of SARS-CoV-2 in Kanagawa Prefecture
Fact-finding survey on subclinical infection of SARS-CoV-2 in Kanagawa Prefecture
Fact-finding survey on subclinical infection of SARS-CoV-2 in Kanagawa Prefecture
Fact-finding survey on subclinical infection of SARS-CoV-2 in Kanagawa Prefecture
Japan |
COVID-19
Medicine in general | Infectious disease |
Others
NO
To investigate the actual condition of clinical sites and analyze the subclinical infection of SARS-CoV-2, the frequency of anamnesis of infection, and the relation to backgrounds in Kanagawa.
Others
epidemiologic study
SARS-CoV-2 positivity rate in IgG antibody tests
Rates of SARS-CoV-2-positive patients in IgG antibody tests for different elements of patient backgrounds
SARS-CoV-2 positivity rate in IgG antibody tests (2,4 and 6 month after being found to be positive)
Clinical symptoms (2,4,6 and 12 month after being found to be positive)
SARS-CoV-2 positivity rate in IgG antibody tests in the doctor/nurse group (in 2021)
Observational
Not applicable |
Not applicable |
Male and Female
1) Patients who regularly visit medical institutions belonging to the Kanagawa Physicians Association or physicians and nurses employed at those institutions
2) All ages eligible
3) Those who are living in Japan and can participate in continuous follow-ups
4) Those who consent to participate in the study (in the case of minors, consent should be obtained from their legal guardian)
1) Those who have tested positive for SARS-CoV-2
2) Those who had cold-like symptoms such as a fever within the past 21 days
3) Those who had cold-like symptoms and/or a fever of 37.5 degrees or more for at least four days in 2020
4) Those who had extreme fatigue and/or dyspnea in 2020
1500
1st name | Ikuro |
Middle name | |
Last name | Matsuba |
Kanagawa Physicians Association
Scientific Committee
231-0037
1-3 Fujimichou, Nakaku, Yokohama, Kanagawa
045-241-7000
ikuro@matsuba-web.com
1st name | Ikuro |
Middle name | |
Last name | Matsuba |
Kanagawa Physicians Association
Scientific Committee
231-0037
1-3 Fujimichou, Nakaku, Yokohama, Kanagawa
045-241-7000
ikuro@matsuba-web.com
Kanagawa Physicians Association
Self funding
Other
Kanagawa Physicians Association Ethical Review Special Committee
1-3 Fujimichou, Nakaku, Yokohama, Kanagawa
045-241-7000
info@kanagawa.med.or.jp
NO
2020 | Year | 05 | Month | 08 | Day |
https://www.jiac-j.com/article/S1341-321X(20)30325-1/fulltext
Published
https://www.jiac-j.com/article/S1341-321X(20)30325-1/fulltext
1603
The 39 in 1603 subjects (2.4%) were found to be IgG antibody-positive: 29 in the patient group (2.9%), 10 in the doctor/nurse group (2.0%), and 0 in the control group. After adjustment for age, sex, and the antibody prevalence in the control group, antibody prevalence was 2.7% in the patient group and 2.1% in the doctor/nurse group.
Intern Med. 2022 Jan 15;61(2):159-165. doi: 10.2169/internalmedicine.8019-21.
Intern Med. 2022 Oct 15;61(20):3053-3062. doi: 10.2169/internalmedicine.
2021 | Year | 11 | Month | 08 | Day |
2020 | Year | 09 | Month | 06 | Day |
The 39 in 1603 subjects (2.4%) were found to be IgG antibody-positive: 29 in the patient group (2.9%), 10 in the doctor/nurse group (2.0%), and 0 in the control group.
We then obtained consent from 33 of the 39 subjects who tested positive and performed follow-up for 12 months. Results Follow-up for up to 12 months showed that a long-term response of the anti-N IgG antibody could be detected in 6 of the 33 participants (18.2%).
nothing
After adjustment for age, sex, and the antibody prevalence in the control group, antibody prevalence was 2.7% in the patient group and 2.1% in the doctor/nurse group.
We then obtained consent from 33 of the 39 subjects who tested positive and performed follow-up for 12 months. Results Follow-up for up to 12 months showed that a long-term response of the anti-N IgG antibody could be detected in 6 of the 33 participants (18.2%).
Completed
2020 | Year | 04 | Month | 18 | Day |
2020 | Year | 04 | Month | 27 | Day |
2020 | Year | 05 | Month | 19 | Day |
2021 | Year | 07 | Month | 30 | Day |
Obtain consent from the subject and then conduct an antibody test using serum followed by a survey.
2020 | Year | 05 | Month | 08 | Day |
2022 | Year | 11 | Month | 08 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046025
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |